Building on deep scientific knowledge gained from decades of experience with viruses such as MERS, SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have made unprecedented progress in advancing treatments and vaccines to help fight COVID-19. At this time, three vaccines and several treatments have received emergency use authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) with one treatment receiving FDA approval. Additional candidates under investigation have also shown promise.
